Sobre 1 señal de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Explore the full record of transactions filed by Greenleaf Peter, Director. Officer active across 4 companies, notably Pelthos Therapeutics Inc.. Cumulatively, 20 reports have been published. Breakdown: 1 buy · 6 sells. Total volume traded: €977k. History available since 11 May 2021. The latest transaction was disclosed on 2 July 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Greenleaf Peter
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2133 títulos@ 10,15 US$0.8% de su flujoCommon StockSEC:0001628280-21-010022:0
Salida canónica: 9 ago 2021 (T+90)
20 de 20 declaraciones
About Greenleaf Peter
Peter Greenleaf is a Director and Chief Executive Officer of Pelthos Therapeutics Inc., Aurinia Pharmaceuticals Inc., and ANTARES PHARMA, INC. He leads these companies with a focus on innovation and the development of new treatments.